I've been relatively optimistic about St. Jude Medical's (NYSE:STJ)
long-term prospects as the company navigates its current multi-year
lull in growth. The company has a legitimate presence in important
markets like cardiac rhythm management, atrial fibrillation,
neurostimulation, and heart valve replacement, plus a pipeline that
could reignite growth. With all of that said, it's still getting harder
to ignore the realities of just how growth-challenged the company is in
the here and now. Although I do believe the long-term expectations for
St. Jude are increasingly beatable, this could be a frustrating stock to
own for a little while yet.
Please read more here:
http://www.investopedia.com/stock-analysis/041813/broad-weakness-makes-it-harder-st-jude-today-stj-bsx-mdt-ew-jnj-atrc.aspx
No comments:
Post a Comment